Barclays
CRBP icon

Barclays’s Corbus Pharmaceuticals CRBP Stock Holding History

Barclays’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-85,000
Closed -$1.75M – 5306
2024
Q3 		$1.75M Buy
+85,000
New +$4.35M ﹤0.01% 2960

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Barclays's CRBP Position: Q2 2026 in Review

Barclays reduced its Corbus Pharmaceuticals (CRBP) stake by 61% in Q2 2026, selling an estimated $121K and leaving 8,002 shares worth $75.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4173.

Barclays first reported a position in CRBP in Q4 2016 and has held it in 30 quarters since. The position peaked at $7.27M in Q1 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Barclays held 8,002 shares of Corbus Pharmaceuticals worth $75.1K as of Q2 2026.
  • Barclays sold 12,780 Corbus Pharmaceuticals shares in Q2 2026, an estimated $121K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4173 holding.
  • Barclays first reported a position in Corbus Pharmaceuticals in Q4 2016 and has held it in 30 quarters since.
  • Barclays's Corbus Pharmaceuticals position peaked at $7.27M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.